摘要
米那普仑是一种新型抗抑郁药,对5-羟色胺(5-HT)及去甲肾上腺素(NE)的再摄取具有双重抑制作用,且强度相当。口服米那普仑具有较高的生物利用度和较低的血浆蛋白结合力,大部分以原型或葡萄糖酸苷的形式从尿中清除,与其他药物相互作用少。米那普仑的抗抑郁疗效与三环类相似,可能优于选择性5-羟色胺回收抑制剂(SSRIs),且耐受性良好。每日2次口服,50～150 mg·d^(-1)。该药为抑郁症的药物治疗提供了一种新的选择。
Milnacipran is a new antidepressant that inhibits the reuptake of both serotonin （5-HT） and norepinephrine （NE） with approximately equal potency. Milnacipran has a high bioavailability, low plasma protein binding, and that it is largely eliminated in the urine as parent drug or as a glucuronide and has few interaction with other drugs. Milnacipran is as effective as tricyclic antidepressants （TCAs） and significantly superior to the selective serotonin reuptake inhibitors （SSRIs） in the treatment of patients with depression, and is better tolerated. The daily dose is 50 - 150 mg, twice a day. Milnacipran is a new antidepressant available.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2006年第5期384-388,共5页
Chinese Journal of New Drugs and Clinical Remedies
